Try Calculator
← Back to Compound Library WEIGHT LOSS / METABOLIC

5-Amino-1MQ (NNMT Inhibitor)

5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule compound that functions as an inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that plays a central role in cellular metabolism and fat storage. Unlike most metabolic compounds, 5-Amino-1MQ is not a peptide—it is a small molecule with unique pharmacological properties that allow it to be administered both orally and via subcutaneous injection. The compound was developed by researchers at the University of Texas Medical Branch who were investigating novel approaches to treating obesity and metabolic dysfunction. In animal studies, mice treated with 5-Amino-1MQ demonstrated significant reductions in body fat without any decrease in food intake. The fat loss occurred entirely through increased cellular energy expenditure—a fundamentally different mechanism than GLP-1 receptor agonists like semaglutide, which primarily work through appetite suppression. What makes 5-Amino-1MQ particularly interesting is its mechanism of action: by inhibiting NNMT, it prevents the wasteful degradation of nicotinamide (a form of vitamin B3) and thereby preserves NAD+ (nicotinamide adenine dinucleotide), a critical coenzyme required for mitochondrial energy production. This creates a cascade of metabolic improvements including enhanced fat oxidation, improved insulin sensitivity, and potential benefits for cellular aging processes. 5-Amino-1MQ is currently a research compound and has not been approved by the FDA for human use. Human clinical trial data is limited, though preclinical evidence from animal studies is promising. The compound is available through research chemical suppliers.

How It Works

To understand how 5-Amino-1MQ works, you need to understand the metabolic pathway it affects and why NNMT inhibition produces beneficial effects on fat metabolism and cellular energy.

The NAD+ Salvage Pathway and NNMT

Your mitochondria are the cellular power plants responsible for converting the food you eat into usable energy in the form of ATP (adenosine triphosphate). NAD+ is essential for this process— it functions as an electron shuttle that transfers electrons from nutrients into the electron transport chain where ATP is produced. Your body produces NAD+ primarily through the salvage pathway, which recycles nicotinamide (a breakdown product of NAD+) back into new NAD+. This salvage pathway is responsible for approximately 80% of total NAD+ production and is critical for maintaining cellular energy levels. However, your body also expresses an enzyme called NNMT that competes for the same nicotinamide substrate. NNMT methylates nicotinamide into 1-methylnicotinamide (1-MNA), a metabolic waste product that is excreted in urine. Under normal physiological conditions, this serves as a regulatory mechanism to prevent excessive nicotinamide accumulation.

NNMT Overexpression in Obesity

The problem begins with obesity and metabolic dysfunction. Research has demonstrated that NNMT expression is significantly elevated in adipose tissue (fat cells) of obese individuals compared to lean individuals. This creates a pathological situation:

This creates a vicious cycle: obesity increases NNMT expression → NNMT depletes NAD+ in fat cells → reduced NAD+ impairs fat burning → more fat accumulation → further NNMT upregulation.

How 5-Amino-1MQ Breaks the Cycle

5-Amino-1MQ functions as a selective NNMT inhibitor. When you administer 5-Amino-1MQ, it blocks the NNMT enzyme, which produces several beneficial effects:

The critical point is that 5-Amino-1MQ does not suppress appetite or reduce food intake. It works by increasing cellular energy expenditure—your cells become more metabolically active and burn more energy, particularly from fat stores.

Target Population and Mechanistic Context

This mechanistic understanding has important implications for who will benefit most from 5- Amino-1MQ: Research demonstrates that NNMT overexpression correlates strongly with body fat percentage and metabolic dysfunction, not simply with aging. The most dramatic results from animal studies were observed in diet-induced obese mice—animals with pathologically elevated NNMT activity. Blocking NNMT in these animals corrected an existing metabolic dysfunction. In lean individuals with normal metabolic function, adipose NNMT expression is at baseline levels. There is no pathological overexpression creating a drain on NAD+ synthesis. If there is no dysfunction present, there is nothing to correct. Therefore, based on the mechanism of action, 5-Amino-1MQ is most appropriate for individuals with:

Lean individuals seeking additional metabolic optimization may not experience the same magnitude of benefit because the underlying pathology (NNMT overexpression) is not present.

Benefits

The benefits of 5-Amino-1MQ are supported primarily by preclinical animal research. Human data is limited, so effects in humans should be considered theoretical until clinical trials are completed.

Significant Fat Loss Without Appetite Suppression

The primary benefit demonstrated in animal research is substantial fat reduction through increased cellular energy expenditure rather than reduced caloric intake. In the landmark 2017 Neelakantan et al. study published in Biochemical Pharmacology, diet-induced obese mice treated with 5-Amino-1MQ showed:

The fat loss occurred purely through metabolic changes—increased energy expenditure and enhanced fat oxidation—without any behavioral changes or appetite suppression.

Preserved Lean Muscle Mass

Unlike simple caloric restriction, which often results in loss of both fat and muscle tissue, NNMT inhibition appears to preserve lean tissue while selectively reducing fat mass. The elevated NAD+ levels and SIRT1 activation support protein synthesis and reduce muscle catabolism during fat loss phases. This makes 5-Amino-1MQ potentially valuable during body recomposition phases where maintaining muscle mass is critical.

Improved Insulin Sensitivity and Glucose Metabolism

Animal studies demonstrate improvements in glucose tolerance and insulin sensitivity with NNMT inhibition. The 2024 Babula et al. study published in Diabetes, Obesity and Metabolism found that 5-Amino-1MQ treatment:

These metabolic improvements make sense given the well-established relationship between excess adipose tissue and insulin resistance.

Enhanced Muscle Regeneration and Function

A 2019 study by Neelakantan et al. published in Biochemical Pharmacology examined the effects of 5-Amino-1MQ on aged skeletal muscle. The researchers found that NNMT inhibition:

This suggests potential applications beyond fat loss, including muscle preservation during aging and enhanced recovery from training.

Liver Health and Hepatic Function

The 2024 Babula et al. study demonstrated that 5-Amino-1MQ treatment improved liver pathology markers in obese mice. Given the prevalence of non-alcoholic fatty liver disease (NAFLD) in obesity, compounds that improve hepatic metabolism may have broader metabolic health benefits.

Gut Microbiome Modulation

A 2022 study by Dimet-Wiley et al. published in Scientific Reports found that combining 5- Amino-1MQ treatment with a diet switch from high-fat to lower-fat produced remarkable results:

never been obese

This suggests that 5-Amino-1MQ may work through multiple mechanisms including modulation of the gut-metabolism axis.

Potential Longevity and Anti-Aging Effects

By preserving NAD+ and activating SIRT1 (a key longevity protein), NNMT inhibition may have broader implications for cellular aging processes:

While these effects are theoretical in humans, they align with known functions of NAD+ and sirtuins in aging biology.

What the Science Shows

5-Amino-1MQ has substantial preclinical research from peer-reviewed journals but limited human clinical data. The research has been conducted primarily by groups at the University of Texas Medical Branch.

Neelakantan et al. (2017) – Foundational NNMT Inhibition Study Published in Biochemical Pharmacology. This landmark study validated 5-Amino-1MQ as an effective and selective NNMT inhibitor. Key findings:

waste product of NNMT

This study established proof of concept that pharmacological NNMT inhibition could reverse diet-induced obesity in animal models.

Kraus et al. (2014) – NNMT Knockdown Study

Published in Nature. While not specifically about 5-Amino-1MQ, this influential study demonstrated the metabolic consequences of NNMT reduction. Key findings:

This study provided the mechanistic foundation that led to development of pharmacological NNMT inhibitors like 5-Amino-1MQ.

Neelakantan et al. (2019) – Muscle Regeneration Study

Published in Biochemical Pharmacology. This study examined effects on aged skeletal muscle. Key findings:

This expanded the potential applications of NNMT inhibition beyond fat loss to include muscle preservation and function during aging.

Dimet-Wiley et al. (2022) – Diet Combination Study

Published in Scientific Reports. This study examined combining NNMT inhibition with dietary intervention. Key findings:

complete normalization of body weight and fat mass

This suggests that 5-Amino-1MQ may be most effective when combined with appropriate dietary modifications.

Babula et al. (2024) – Pharmacokinetics and Metabolic Effects Published in Diabetes, Obesity and Metabolism. The most recent study examining pharmacokinetic properties and metabolic outcomes. Key findings:

This study provided the most comprehensive characterization of 5-Amino-1MQ’s metabolic effects and pharmacological properties. Sources:

molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2017;147:141-152.

against diet-induced obesity. Nature. 2014;508:258-262.

methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481-492. https://pubmed.ncbi.nlm.nih.gov/30802456/

inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022;12:1- 13. https://pubmed.ncbi.nlm.nih.gov/35042884/

mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(11):5272-5282. https://pubmed.ncbi.nlm.nih.gov/39248180/

Enzyme. Journal of Clinical Endocrinology and Metabolism. 2015;100(8):3112-3114.

Research Dosing Protocol

Dosing 5-Amino-1MQ requires careful consideration of pharmacokinetic principles. The compound has been studied in animals but lacks robust human clinical data, so dosing recommendations are extrapolated from animal studies using allometric scaling and pharmacokinetic modeling.

Understanding Effective Dosing

For a drug to produce its intended effect, it must achieve adequate tissue concentrations to inhibit at least 50% of its target enzyme—this is called IC50 coverage. Below this threshold, the compound is unlikely to produce meaningful biological effects. The animal studies showing efficacy used doses that translate to approximately 400 mg per day for humans using standard allometric scaling (accounting for differences in body surface area and metabolic rate between species). However, you will find online recommendations ranging from 150 micrograms to 150 milligrams per day—a variance of 1,000-fold. This enormous discrepancy exists because:

Based on pharmacokinetic modeling using structural analogs like metformin (similar molecular weight, charge distribution, oral bioavailability, and half-life), achieving 50% NNMT inhibition requires approximately 50-100 mg per day. For near-complete enzyme inhibition, doses of 400- 600 mg per day would theoretically be needed. Microdoses in the range of 150-600 micrograms per day are approximately 400-fold below the threshold needed for meaningful enzyme inhibition. While such doses may produce subjective effects in some users, they are unlikely to achieve the degree of NNMT inhibition demonstrated in animal efficacy studies.

Recommended Dosing Protocols

Oral Administration:

circulation)

Subcutaneous Administration:

similar tissue concentrations Cycling Protocol:

responses that reduce effectiveness Important Considerations: Morning dosing is essential. 5-Amino-1MQ can interfere with sleep architecture if taken later in the day due to its energizing metabolic effects. Cost considerations. At effective doses (50-100 mg daily), a 50 mg vial lasts approximately 1 day, making this compound economically prohibitive for many users. This cost barrier is why many online protocols suggest subtherapeutic microdoses that may not achieve meaningful results.

Reconstitution Instructions (for Injectable Use)

Side Effects and Safety

5-Amino-1MQ has limited human safety data. Animal studies reported no observable adverse effects at the doses tested, and anecdotal community reports are generally favorable. However, individual responses vary, and long-term safety in humans is unknown. Commonly Reported Effects:

first week)

What We Do Not Know:

Theoretical Concerns:

NNMT plays diverse roles beyond fat metabolism. It has been studied in contexts including cancer biology, Parkinson’s disease, and cellular detoxification. NNMT expression is altered in various cancer types—sometimes elevated, sometimes reduced—and its role appears to be tissue-specific and context-dependent. The long-term implications of chronic pharmacological NNMT inhibition are not fully understood. While short-term animal studies show favorable outcomes, chronic suppression of an enzyme with diverse biological functions warrants caution. Contraindications – Do Not Use If You Have:

of inhibition are unknown)

Use With Caution If You Have:

Not a Substitute For:

Success Tips

Pair With a Moderate Caloric Deficit

5-Amino-1MQ increases cellular energy expenditure and enhances fat oxidation, but these effects are optimized when you provide your body with fat to mobilize and burn. A moderate caloric deficit of 300-500 calories below maintenance combined with NNMT inhibition will produce better results than either approach alone. Extreme caloric restriction is not necessary and may be counterproductive. The compound works by improving metabolic efficiency, not by forcing starvation.

Prioritize Resistance Training

The 2019 Neelakantan muscle regeneration study demonstrated that 5-Amino-1MQ combined with exercise produced superior improvements in muscle function compared to either intervention alone. The compound appears to enhance the body’s adaptive response to training. Resistance training 2-4 times per week will:

Morning Dosing Only

Administer 5-Amino-1MQ in the morning to align with natural circadian metabolic rhythms and avoid potential sleep interference. The compound’s energizing effects can disrupt sleep architecture if taken in the afternoon or evening.

Track Body Composition, Not Just Scale Weight

Because 5-Amino-1MQ may preserve or even enhance lean tissue while reducing fat mass, scale weight alone may not accurately reflect progress. Consider:

Consider NAD+ Precursor Supplementation

While 5-Amino-1MQ preserves existing NAD+ by blocking the NNMT degradation pathway, adding NAD+ precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) provides additional building blocks for NAD+ synthesis. The combination approach:

This dual approach may produce synergistic effects on cellular energy and metabolic function.

Be Realistic About Timeline

Some users report increased energy within days of starting 5-Amino-1MQ. However, meaningful body composition changes typically become apparent over 2-4 weeks when combined with appropriate diet and exercise. This is not a rapid weight loss compound. It works by improving metabolic efficiency at the cellular level, which produces gradual, sustainable changes rather than dramatic short-term results.

Storage and Handling

Before Reconstitution:

After Reconstitution:

Legal Status

United States: Not FDA approved for human use. Available through research chemical suppliers for research purposes only. WADA Status: Not currently listed on the World Anti-Doping Agency prohibited list (as of 2025). Athletes should verify current status with their governing bodies before use. Research and Development Status: The compound is being developed commercially by Ridgeline Therapeutics for potential therapeutic applications. Preclinical data is robust, but no completed human clinical trials have been published.

Frequently Asked Questions

How is 5-Amino-1MQ different from GLP-1 drugs like semaglutide? GLP-1 receptor agonists like semaglutide work primarily through appetite suppression and delayed gastric emptying—you eat less and feel full longer. 5-Amino-1MQ works by increasing cellular energy expenditure through NNMT inhibition and NAD+ preservation. You may not experience appetite changes, but your metabolism becomes more efficient at mobilizing and burning stored fat. The mechanisms are completely different and potentially complementary. Can 5-Amino-1MQ be taken orally? Yes. Unlike peptides which are destroyed by digestive enzymes, 5-Amino-1MQ is a small molecule that survives the digestive system intact. Oral bioavailability is approximately 38%, meaning about 38% of an oral dose reaches systemic circulation. Subcutaneous injection bypasses first-pass metabolism, so more of the compound reaches the bloodstream at the same dose. How quickly will I see results? Individual responses vary considerably. Some users report increased energy and improved workout performance within the first few days. Measurable body composition changes typically become apparent over 2-4 weeks when 5-Amino-1MQ is combined with appropriate nutrition and exercise. This is not a rapid weight loss compound—it works by improving metabolic efficiency, which produces gradual, sustainable changes. What about microdosing protocols (150-600 mcg per day)? Microdoses in this range do not make pharmacological sense based on known principles of enzyme inhibition. At 150-600 micrograms per day, you are approximately 400-fold below the concentration threshold needed for 50% NNMT inhibition. While some users report subjective effects at these doses, they are unlikely to achieve the degree of enzyme inhibition demonstrated in animal efficacy studies. Effective dosing requires approximately 50-100 mg daily minimum.

Microdose protocols exist primarily because effective doses are economically prohibitive for most users, not because they are pharmacologically optimal. Is 5-Amino-1MQ the same as NMN or NAD+ supplements? No. NMN (nicotinamide mononucleotide) and other NAD+ precursors work by directly providing building blocks for NAD+ synthesis. 5-Amino-1MQ works by preventing NAD+ from being depleted through the NNMT degradation pathway. They are complementary approaches with different mechanisms. NMN provides substrate; 5-Amino-1MQ plugs the leak. Will I regain weight after stopping 5-Amino-1MQ? The metabolic changes induced by NNMT inhibition are not permanent. If you return to a caloric surplus and sedentary lifestyle after discontinuing the compound, weight regain is likely. 5- Amino-1MQ should be viewed as a tool to facilitate fat loss and metabolic improvement, not as a permanent solution. Sustainable results require sustainable lifestyle modifications including appropriate nutrition, regular exercise, adequate sleep, and stress management. I’m lean and metabolically healthy. Should I use 5-Amino-1MQ? Probably not. The mechanism of action corrects NNMT overexpression, which research shows correlates primarily with excess body fat and metabolic dysfunction. In lean individuals with normal metabolic function, adipose NNMT expression is at baseline levels—there is no pathological overexpression creating a drain on NAD+ synthesis. If there is no underlying dysfunction present, there is nothing to correct. The dramatic results observed in animal studies occurred in diet-induced obese mice with pathologically elevated NNMT. Lean individuals are unlikely to experience the same magnitude of benefit. Can 5-Amino-1MQ be combined with other metabolic compounds? Potentially, yes. Because 5-Amino-1MQ works through a unique mechanism (NNMT inhibition), it may be complementary to other approaches. However, there is no clinical research on combination protocols, so any stacking should be approached cautiously. If combining with NAD+ precursors, GLP-1 agonists, or other metabolic compounds, start with lower doses and monitor for unexpected effects.

References

molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2017;147:141-152.

against diet-induced obesity. Nature. 2014;508:258-262.

methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481-492. https://pubmed.ncbi.nlm.nih.gov/30802456/

inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022;12:1- 13. https://pubmed.ncbi.nlm.nih.gov/35042884/

mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(11):5272-5282. https://pubmed.ncbi.nlm.nih.gov/39248180/

Enzyme. Journal of Clinical Endocrinology and Metabolism. 2015;100(8):3112-3114.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch